Book a Meeting

Fc Engineered Anti-Human PDGFRA Therapeutic Antibody, a CDC-Enhanced Biobetter [Lot: CB20-PZ16] (CAT#: BioBet-C016ZP) Datasheet

Target
PDGFRA
Isotype
Whole Human Antibody
Description
CDC-Enhanced Olaratumab is a Fc-modified anti-PDGFRA therapeutic biobetter antibody. Creative Biolabs' advanced CDC-enhanced antibody platform allows for the production of Fc engineered therapeutic CDC⁺ antibodies. By mutating key amino acids of the Fc region of Olaratumab, Olaratumab exhibits a greater binding capacity to C1q, thereby achieving enhanced CDC activity.
Indication
Soft Tissue Sarcoma (STS)
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Olaratumab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
PDGFRA
Full Name
platelet derived growth factor receptor alpha
Background
This gene encodes a cell surface tyrosine kinase receptor for members of the platelet-derived growth factor family. These growth factors are mitogens for cells of mesenchymal origin. The identity of the growth factor bound to a receptor monomer determines whether the functional receptor is a homodimer or a heterodimer, composed of both platelet-derived growth factor receptor alpha and beta polypeptides. Studies suggest that this gene plays a role in organ development, wound healing, and tumor progression. Mutations in this gene have been associated with idiopathic hypereosinophilic syndrome, somatic and familial gastrointestinal stromal tumors, and a variety of other cancers.
Alternative Names
Platelet Derived Growth Factor Receptor Alpha; Platelet-Derived Growth Factor Receptor, Alpha Polypeptide; Alpha-Type Platelet-Derived Growth Factor Receptor; Platelet-Derived Growth Factor Receptor 2; CD140 Antigen-Like Family Member A; CD140a Antigen; PDGF-R-Alpha; EC 2.7.10.1; PDGFR-2;
Gene ID
5156
UniProt ID
P16234
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
Whole Human Antibody
Description
Olaratumab is a fully human IgG1 monoclonal antibody that targets platelet-derived growth factor receptor alpha. It was developed by Eli Lilly and was approved in October 2016 (as Lartruvo) as the initial treatment for certain types of soft tissue sarcoma (STS) adults. Studies have shown that combining olaratumab with adriamycin can significantly reduce the proliferation of cancer cells and tumor growth.
Indication
Soft Tissue Sarcoma (STS)
Synonyms
IMC-3G3, LY-3012207

PDGFR signaling is a tyrosine kinase-mediated pathway that normally regulates cell growth, chemotaxis, and mesenchymal stem cell differentiation. Olaratumab is a fully human IgG1 monoclonal antibody with antitumor activity and can selectively bind to the outer domain of human platelet-derived growth factor receptor (PDGFR) -α with high affinity. Olaratumab blocks ligand-induced tumor cell proliferation and inhibits receptor autophosphorylation and ligand-induced phosphorylation of downstream signaling molecules protein kinase B (Akt) and mitogen-activated protein kinase 5.

Olaratumab in combination with adriamycin for the treatment of adult patients with advanced or metastatic soft tissue sarcoma (STS) of histological subtype

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany